Latest Percutaneous coronary intervention Stories
Connie K. Ho for redOrbit.com – Your Universe Online Heart attacks can happen at any moment. They might be triggered by a factor related to diet or exercise, but the question remains as to what happens to patients following treatment. Recently, researchers from Harvard School of Public Health (HSPH) ventured on a mission to analyze data pooled from 100,000 Medicare patients who had suffered a heart attack and the effects that public reporting might have on percutaneous coronary...
NATICK, Mass., Sept. 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge(TM) Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in...
TEL AVIV, Israel, September 27, 2012 /PRNewswire/ -- Trial Studied Performance Of MGuard(TM) Embolic Protection Stent (EPS) In 433 Patients Undergoing Emergency Treatment For Heart Attacks InspireMD, Inc. (OTCBB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary MGuard(TM) embolic protection stent platform technology for use in patients with Acute Myocardial...
MIAMI BEACH, Fla., Sept. 20, 2012 /PRNewswire-USNewswire/ -- The Journal of Thoracic and Cardiovascular Surgery (September 2012) has published a Mount Sinai Medical Center of Miami Beach study that reports the superiority of a hybrid approach to treating coronary valvular disease. The study revealed that patients who had coronary artery intervention (stenting) combined with minimally invasive valve surgery had significantly better outcomes than patients who had standard sternotomy...
BASKING RIDGE, N.J., Sept. 12, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the UBS Global Life Sciences Conference at 2:00 p.m. ET on September 19, 2012 at the Grand Hyatt in New York City. The presentation will include an overview of the Company's pipeline with emphasis on the lead development program,...
TEL AVIV, Israel, September 12, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary embolic protection stent platform technology for use in patients with Acute Myocardial Infarctions, today announced financial results for the six months ended June 30, 2012. As previously announced, the Company changed its fiscal year end to June 30. As a result,...
BASKING RIDGE, N.J, Aug. 29, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Stifel Nicolaus Healthcare Conference 2012 at 3:15 p.m. ET on September 5, 2012 at the Four Seasons Hotel in Boston, MA. The presentation will include an overview of the Company's pipeline with emphasis on the lead development...
The analysis of data from two Swedish registries was presented by Dr Anders Ulvenstam, and suggests that the reduction is due to improvements in AMI care. Ischemic stroke is a well known, relatively rare but potentially devastating complication following myocardial infarction. It can lead to severe neurological handicap and death for the patient and it is associated with great costs for society. "The risk of ischemic stroke after myocardial infarction has been studied previously, but...
WASHINGTON, Aug. 28, 2012 /PRNewswire/ -- The FAME 2 trial will improve treatment strategies for patients with stable ischemic heart disease. FAME 2 indicates that angioplasty and stenting (also known as percutaneous coronary intervention, or PCI) plus the best available medications results in better outcomes than medications alone for patients who have significant blockages in their heart arteries, as measured by a test known as Fractional Flow Reserve (FFR). With these results,...
MUNICH and WAYNE, N.J., Aug. 27, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, the market leader in intra-aortic balloon counterpulsation therapy, today announced 30-day results from the large, randomized, multicenter IABP- SHOCK II ("SHOCK II") clinical trial in patients with acute myocardial infarction (AMI) who were in cardiogenic shock and undergoing early revascularization. The findings showed that use of intra-aortic balloon counterpulsation (IABC) therapy was associated with...
